All In Biotech

Drug Trial Radar · NCT06975787

Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis

A Dose Escalation Study Investigating Bispecific Antibody Therapy in Patients With Lupus Nephritis

Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

90

Planned (sponsor's estimate)

Start

Dec 22, 2025

Primary completion

Sep 10, 2029

Study completion Sep 10, 2029

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
First posted
May 16, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is researching a particular group of experimental drugs administered for a short period in the treatment of participants with Lupus Nephritis (LN). The main aim of the current study is to see how safe and tolerable the study drugs are in a long-term follow-up. This is a main study, called an umbrella study, which includes several independent smaller sub-studies. Each of these smaller main sub-studies tests different drugs at the same time, all aimed at treating LN. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)

Conditions

  • Lupus Nephritis (LN)

Interventions

  • VonsetamigDrug

    Administered as per the protocol

  • OdronextamabDrug

    Administered as per the protocol

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Occurrence of Dose Limiting Toxicities (DLT)Time frame: Up to 56 days
  2. Occurrence of Treatment Emergent Adverse Events (TEAEs)Time frame: Through week 76
  3. Severity of TEAEsTime frame: Through week 76

Locations

20 sites in 6 countries. Site status is shown where the registry gives one.

  • University of California San Francisco - Zuckerberg San Francisco General

    San Francisco, California · Recruiting

  • University of Florida

    Gainesville, Florida · Recruiting

  • Mayo Clinic

    Rochester, Minnesota · Recruiting

  • Baylor College of Medicine

    Houston, Texas · Recruiting

  • Centre Hospitalier Universitaire (CHU) Bordeaux

    Bordeaux, New Aquitaine, France · Recruiting

  • University Medical Center of the Johannes Gutenberg-University Mainz

    Mainz, Germany · Recruiting

  • University Hospital Regensburg

    Regensburg, Bavaria, Germany · Recruiting

  • Seoul National University Hospital

    Seoul, South Korea · Recruiting

  • Samsung Medical Center

    Seoul, South Korea · Recruiting

  • Yonsei University College of Medicine, Severance Hospital

    Seoul, South Korea · Recruiting

  • Hallym University Sacred Heart Hospital

    Anyang-si, Gyeonggi-do, South Korea · Recruiting

  • Hospital Gregorio Maranon

    Madrid, Spain · Recruiting

  • Hospital Universitario 12 de Octubre

    Madrid, Spain · Recruiting

  • Hospital Regional Universitario de Malaga

    Málaga, Spain · Recruiting

  • Hospital Universitario Virgen del Rocio

    Seville, Andalusia, Spain · Recruiting

  • Clinica Universidad de Navarra

    Pamplona, Navarre, Spain · Recruiting

  • Changhua Christian Hospital

    Changhua, Taiwan · Recruiting

  • Taichung General Veterans Hospital

    Taichung, Taiwan · Recruiting

  • National Taiwan University Hospital

    Taipei, Taiwan · Recruiting

  • Taipei Veterans General Hospital

    Taipei, Taiwan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.